Overview
Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control
Status:
Completed
Completed
Trial end date:
2009-10-01
2009-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients with inadequate glycaemic control with diet and exercise.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AstraZenecaCollaborator:
Bristol-Myers SquibbTreatments:
Saxagliptin
Criteria
Inclusion Criteria:- Diagnosed with Type 2 diabetes
- Patients should be drug naïve ie, not received medical treatment for diabetes,
- HbA1c ≥ 7.2% and ≤10.0% (at enrolment), HbA1c ≥ 7.0% and ≤10.0% (at randomization)
Exclusion Criteria:
- Insulin therapy within one year of enrolment (with the exception of insulin therapy
during a hospitalization or use in gestational diabetes),
- Type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma